Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-01-13
2009-08-11
McKane, Joseph K (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S448000, C549S063000, C549S064000, C549S069000
Reexamination Certificate
active
07572826
ABSTRACT:
The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, R4, R5and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
REFERENCES:
patent: 3963750 (1976-06-01), Goudie
patent: 5258357 (1993-11-01), Muenster et al.
patent: 5571810 (1996-11-01), Matsuo et al.
patent: 5679670 (1997-10-01), Dean et al.
patent: 6048880 (2000-04-01), Kawai et al.
patent: 6380214 (2002-04-01), Gant et al.
patent: 6414013 (2002-07-01), Fancelli et al.
patent: 6699854 (2004-03-01), Wang et al.
patent: 6809088 (2004-10-01), Chabrier de Lassauniere et al.
patent: 6835745 (2004-12-01), Coghlan et al.
patent: 6875790 (2005-04-01), Bertenshaw et al.
patent: 6881735 (2005-04-01), Schindler et al.
patent: 6881741 (2005-04-01), Kong et al.
patent: 7019027 (2006-03-01), Linden et al.
patent: 7084170 (2006-08-01), Grossman et al.
patent: 7084171 (2006-08-01), Grainger et al.
patent: 7098240 (2006-08-01), Griffiths et al.
patent: 7125896 (2006-10-01), Faull et al.
patent: 7166639 (2007-01-01), Wan et al.
patent: 7196106 (2007-03-01), Duffy et al.
patent: 7358376 (2008-04-01), Baxter et al.
patent: 2006/0058522 (2006-03-01), Faull et al.
patent: 2006/0111431 (2006-05-01), Morley et al.
patent: 2007/0015819 (2007-01-01), Faull et al.
patent: 0202538 (1986-11-01), None
patent: 0853083 (1998-07-01), None
patent: 0908456 (1999-04-01), None
patent: 1468012 (1977-03-01), None
patent: 2195634 (1988-04-01), None
patent: WO 98/02430 (1998-01-01), None
patent: WO 98/54116 (1998-12-01), None
patent: WO 99/46244 (1999-09-01), None
patent: WO 00/71532 (2000-11-01), None
patent: WO 01/58890 (2001-08-01), None
patent: WO 01/98290 (2001-12-01), None
patent: WO 02/30353 (2002-04-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 03/010158 (2003-02-01), None
patent: WO 03/010163 (2003-02-01), None
patent: WO 03/028731 (2003-04-01), None
patent: WO 03/029241 (2003-04-01), None
patent: WO 2004/063185 (2004-07-01), None
patent: WO 2004/063186 (2004-07-01), None
U.S. Appl. No. 09/868,884, filed Feb. 5, 2002, to Baxter, et al.
Karen, M. et al. “NF-kB in cancer: from innocent bystander to major culprit,”Nat. Rev. Cancer, 2: 301-310 (2002).
Luo et al., “IKK/NF-kB signaling: balancing life and death—a new approach to cancer therapy,”J. of Clin. Inv., 115:10: 2625 (2005).
Orlowski, et al., “NF-kB as a therapeutic target in cancer,”Trends in Mol. Med., 8:8: 385 (2002).
Awada et al., “The pipeline of new anticancer agents for breast cancer treatment in 2003”,Critical Rewiews in Oncology/Hematology48:45-63 (2003).
Berkow et al., The Merck Manual of Diagnosis and Therapy, 16thEdition, © 1992, Merck Research Laboratories, Rahway, NJ, pp. 1488 and 2664.
Chen et al., “TNF-R1 Signaling: A Beautiful Pathway”,Science296:1634-1635 (2002).
Compston et al., “Multiple sclerosis”,The Lancet359:1221-1231 (2002).
Du et al., “Aryl ureas represent a new class of anti-trypansomal agents”,Chemistry & Biology7:733-742 (2000).
Goluh et al., “Molecular Classification of Cancer: Class Discovery and Class Predicition by Gene Expression Monitoring”,Science286:531-537 (1999).
Gripenberg, “Common serological features in rheumatoid arthritis and yersinia arthritis”,Scand. J. Rheumatology10:85-91 (1981).
Hartung et al., “What do we know about the mechanism of action of disease-modifying treatments in MS?”J Neurol251(Suppl. 5):V/12-V/29 (2004).
Lala et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors”,Cancer and Metastasis Reviews17:91-106 (1998).
Parrish et al., “Preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders”, CAPLUS 138:304153, 2003.
Zayed et al., “Studies on 5-aminopyrazole derivatives. Synthesis of some new fused pyrazole derivatives”,Monatsh. Chem.115:431-436 (1984).
Cancer [online], [retrieved on Jul. 6, 2007] Retrieved from the Internet, URL; http://www.nlm.nih.gov/medlineplus/cancer.html.
Cancer [online], [retreived on Jul. 6, 2007] Retreived from the Internet, URL; http://en.wikipedia.org/wiki/Cancer.
Diabetes Guide [online], [retreived from the internet on Jun. 17, 2008] [URL; http://www.diabetes.webmd.com/guide/diabetes-overview].
Faull Alan Wellington
Johnstone Craig
Morley Andrew David
Poyser Jeffrey Philip
AstraZeneca AB
Coppins Janet L
Fish & Richardson P.C.
McKane Joseph K
LandOfFree
Thiophene-carboxamide derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiophene-carboxamide derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophene-carboxamide derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4117560